Treatment tolerance is a challenge for most cancer patients, and it is therefore essential that healthcare professionals (HCPs) are quick to recognize adverse events and implement management strategies to address them. Prevention of Nausea and Vomiting in Cancer Patients provides comprehensive guidance on managing nausea and vomiting, which are common and often severe adverse events experienced by patients receiving chemotherapy and radiotherapy. The book refers to the latest American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), and Multinational Association for Supportive Care in Cancer (MASCC) guidelines and will be a useful resource for oncologists, oncology fellows, general physicians, and other HCPs wishing to learn more about the effective management of chemotherapy-and radiotherapy-induced nausea and vomiting in cancer patients.The ASCO guidelines recommend the same combination for multiple days of noncisplatin chemotherapy agents of high ... The MASCC/ESMO guidelines mention the use of a 5-HT3 receptor antagonist on days 1a5, or palonosetron on days 1, ... 1 roila f, hesketh pJ, herrstedt J. prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensusanbsp;...
|Title||:||Prevention of Nausea and Vomiting in Cancer Patients|
|Author||:||Matti Aapro, Karin Jordan, Petra Feyer|
|Publisher||:||Springer Science & Business Media - 2013-11-12|